Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.

Suzuki T, Nakamura Y, Kato H

Modern rheumatology28 Nov 2018Cited by 7 (Europe PMC)

PMID30217118DOI10.1080/14397595.2018.1524997PepBankPUB-30217118

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal Japanese women with osteoporosis, BAP differed significantly between denosumab plus teriparatide and denosumab alone at all reported time points.
In plain wordsIn postmenopausal Japanese women, BAP differed between denosumab plus teriparatide and denosumab alone, but the direction was not reported.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedBone-specific alkaline phosphatase between-group difference
Study
n = 47
Comparator
Denosumab alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · up to 48 monthsAs given in this study (human).
Source sentences
Summary
BAP was significantly decreased from baseline in both groups from 24 to 48 months, with significant differences at all time points between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This extended randomized prospective study aimed to compare the 4-year clinical outcomes of denosumab treatment alone or in combination with teriparatide in treatment-naïve postmenopausal Japanese patients with osteoporosis.
Summary · context
After newly adding 17 randomly assigned patients, 47 patients were classified into the denosumab alone group (denosumab group, n = 22) or denosumab plus teriparatide group (combination group, n = 25).
Report a problemFND-3021711802
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal Japanese women with osteoporosis, TRACP-5b decreases were comparable with denosumab plus teriparatide and denosumab alone.
In plain wordsIn postmenopausal Japanese women, TRACP-5b decreases were similar with denosumab plus teriparatide and denosumab alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTRACP-5b between-group comparison
Study
n = 47
Comparator
Denosumab alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · up to 48 monthsAs given in this study (human).
Source sentences
Summary
TRACP-5b and urinary NTX were comparably decreased at every time point in both groups versus pretreatment levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This extended randomized prospective study aimed to compare the 4-year clinical outcomes of denosumab treatment alone or in combination with teriparatide in treatment-naïve postmenopausal Japanese patients with osteoporosis.
Summary · context
After newly adding 17 randomly assigned patients, 47 patients were classified into the denosumab alone group (denosumab group, n = 22) or denosumab plus teriparatide group (combination group, n = 25).
Report a problemFND-3021711804
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal Japanese women with osteoporosis, urinary NTX decreases were comparable with denosumab plus teriparatide and denosumab alone.
In plain wordsIn postmenopausal Japanese women, urinary NTX decreases were similar with denosumab plus teriparatide and denosumab alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeUrinary NTX between-group comparison
Study
n = 47
Comparator
Denosumab alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · up to 48 monthsAs given in this study (human).
Source sentences
Summary
TRACP-5b and urinary NTX were comparably decreased at every time point in both groups versus pretreatment levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This extended randomized prospective study aimed to compare the 4-year clinical outcomes of denosumab treatment alone or in combination with teriparatide in treatment-naïve postmenopausal Japanese patients with osteoporosis.
Summary · context
After newly adding 17 randomly assigned patients, 47 patients were classified into the denosumab alone group (denosumab group, n = 22) or denosumab plus teriparatide group (combination group, n = 25).
Report a problemFND-3021711806
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal Japanese women with osteoporosis, adding teriparatide to denosumab increased lumbar BMD more at 24 and 30 months.
In plain wordsIn postmenopausal Japanese women, denosumab plus teriparatide increased lumbar bone density more than denosumab alone at 24 and 30 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar BMD increase
Study
n = 47
Comparator
Denosumab alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · up to 48 monthsAs given in this study (human).
Measurements
Lumbar BMD increase
21.1%
combination at 48 months
Lumbar BMD increase
14.2%
denosumab at 48 months
Source sentences
Summary
L-BMD was significantly more increased by combination therapy over denosumab alone at 24 and 30 months (21.1% increase vs. 14.2% increase at 48 months).
2 context sentences(design, population, supporting numbers)
Summary · context
This extended randomized prospective study aimed to compare the 4-year clinical outcomes of denosumab treatment alone or in combination with teriparatide in treatment-naïve postmenopausal Japanese patients with osteoporosis.
Summary · context
After newly adding 17 randomly assigned patients, 47 patients were classified into the denosumab alone group (denosumab group, n = 22) or denosumab plus teriparatide group (combination group, n = 25).
Report a problemFND-3021711807
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal Japanese women with osteoporosis, total hip BMD did not differ significantly between denosumab plus teriparatide and denosumab alone.
In plain wordsIn postmenopausal Japanese women, total hip bone density did not differ significantly between denosumab plus teriparatide and denosumab alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTotal hip BMD
Study
n = 47
Comparator
Denosumab alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · up to 48 monthsAs given in this study (human).
Measurements
Hip BMD increase
9.7%
combination at 48 months
Hip BMD increase
6.8%
denosumab at 48 months
Source sentences
Summary
There were no significant differences in H-BMD between the groups, although levels tended to be higher in the combination group throughout the study period (9.7% increase vs. 6.8% increase at 48 months).
2 context sentences(design, population, supporting numbers)
Summary · context
This extended randomized prospective study aimed to compare the 4-year clinical outcomes of denosumab treatment alone or in combination with teriparatide in treatment-naïve postmenopausal Japanese patients with osteoporosis.
Summary · context
After newly adding 17 randomly assigned patients, 47 patients were classified into the denosumab alone group (denosumab group, n = 22) or denosumab plus teriparatide group (combination group, n = 25).
Report a problemFND-3021711808

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal Japanese women with osteoporosis, BAP decreased from baseline at 24–48 months with both denosumab and denosumab plus teriparatide.
In plain wordsIn postmenopausal Japanese women, BAP decreased from baseline with both denosumab and denosumab plus teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone-specific alkaline phosphatase change
Study
n = 47
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
BAP was significantly decreased from baseline in both groups from 24 to 48 months, with significant differences at all time points between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This extended randomized prospective study aimed to compare the 4-year clinical outcomes of denosumab treatment alone or in combination with teriparatide in treatment-naïve postmenopausal Japanese patients with osteoporosis.
Summary · context
After newly adding 17 randomly assigned patients, 47 patients were classified into the denosumab alone group (denosumab group, n = 22) or denosumab plus teriparatide group (combination group, n = 25).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3021711801
07HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal Japanese women with osteoporosis, TRACP-5b decreased from pretreatment at every time point in both denosumab and denosumab-plus-teriparatide groups.
In plain wordsIn postmenopausal Japanese women, TRACP-5b decreased from baseline in both denosumab and denosumab-plus-teriparatide groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTRACP-5b change
Study
n = 47
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
TRACP-5b and urinary NTX were comparably decreased at every time point in both groups versus pretreatment levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This extended randomized prospective study aimed to compare the 4-year clinical outcomes of denosumab treatment alone or in combination with teriparatide in treatment-naïve postmenopausal Japanese patients with osteoporosis.
Summary · context
After newly adding 17 randomly assigned patients, 47 patients were classified into the denosumab alone group (denosumab group, n = 22) or denosumab plus teriparatide group (combination group, n = 25).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3021711803
08HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal Japanese women with osteoporosis, urinary NTX decreased from pretreatment at every time point in both denosumab and denosumab-plus-teriparatide groups.
In plain wordsIn postmenopausal Japanese women, urinary NTX decreased from baseline in both denosumab and denosumab-plus-teriparatide groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseUrinary NTX change
Study
n = 47
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
TRACP-5b and urinary NTX were comparably decreased at every time point in both groups versus pretreatment levels.
2 context sentences(design, population, supporting numbers)
Summary · context
This extended randomized prospective study aimed to compare the 4-year clinical outcomes of denosumab treatment alone or in combination with teriparatide in treatment-naïve postmenopausal Japanese patients with osteoporosis.
Summary · context
After newly adding 17 randomly assigned patients, 47 patients were classified into the denosumab alone group (denosumab group, n = 22) or denosumab plus teriparatide group (combination group, n = 25).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3021711805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.